It’s an injury that’s as unique as a snowflake yet as ordinary as a drop of rain. Concussions are most often talked about in sports, but they’re extremely common and… Read More
The first FcRn blocker to demonstrate sustained disease control over 24 weeks in antibody positive adult patients: anti-AChR, anti-MuSK, anti-LRP4 Nipocalimab demonstrated a sustained reduction in autoantibody levels, one of… Read More
Welcome to our third annual report where we examine the Canadian health tech investment landscape across public and private markets and provide an overview of key current trends we are seeing. 2024… Read More
Acquisition adds potential novel oral peptide IL23R inhibitor for psoriasis as well as a peptide synthesis, screening and optimization platform to strengthen AbbVie’s pipeline and R&D capabilities NORTH CHICAGO, ILL… Read More
Collaboration leverages AbbVie’s expertise in oncology and immunology drug development and Neomorph’s leading molecular glue discovery platform Neomorph to receive an upfront payment and is eligible to receive future option fees… Read More
